Kølbæk, Pernille
Mors, Ole
Correll, Christoph U.
Østergaard, Søren D. http://orcid.org/0000-0002-8032-6208
Funding for this research was provided by:
Aarhus Universitets Forskningsfond
Riisfort Fonden
Aarhus University | Sundhedsvidenskabelige Fakultet, Aarhus Universitet
Article History
Received: 8 July 2023
Accepted: 23 November 2023
First Online: 16 December 2023
Competing interests
: C.U.C. has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka and served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has also received grant support from Janssen and Takeda and is a stock option holder of LB Pharma. S.D.O. received the 2020 Lundbeck Foundation Young Investigator Prize. Furthermore, S.D.O owns units of mutual funds with stock tickers DKIGI, NBIDE and WEKAFKI, as well as units of exchange traded funds with stock tickers TRET, 2B76 and L0CK. The remaining authors declare no conflicts of interest. Aarhus University, the Feinstein Institute for Medical Research, and MedAvante-ProPhase Inc. each hold one-third of the copyright for the Simplified Negative and Positive Symptoms Interview (SNAPSI).